See below to download the Meeting Impression

This symposium was held during the 55th ERA-EDTA Congress 2018 in Copenhagen, Denmark. Christoph Wanner, Per-Henrik Groop and Colin Baigent discussed the mechanisms and outcomes of sodium glucose co-transporter 2 (SGLT2) inhibition in diabetic kidney disease. Key lessons from the EMPA-REG OUTCOME trial focusing on the effect of empagliflozin on renal and cardiovascular (CV) events were presented. Also, potential underlying mechanisms of the CV and renal protection seen with SGLT2 inhibition were discussed. Finally, three new trials on SGLT2 inhibition were presented and compared to address the question whether SGLT2 inhibitors have any value for patients with established chronic kidney disease (CKD).

Educational information

This is a summary of the PACE symposium entitled 'Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition', held during ERA-EDTA in Copenhagen, Denmark, on May 25, 2018.

The educational objectives of the symposium were to:

Discuss results from the EMPA-REG OUTCOME study

Identify the mechanisms of SGLT2 inhibition

Understand the effect of SGLT2 inhibition in T2DM

Explore currently ongoing trials on SGLT2 inhibition

Faculty

Prof. Christoph Wanner: Key lessons from the EMPA-REG OUTCOME trial

Prof. Per-Henrik Groop: Understanding CKD and SGLT2-inhibition: what are the key mechanisms?

Prof. Colin Baigent: Addressing the remaining questions on SGLT2 and CKD: a review of new outcome trials

Disclosures

This symposium was supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

Download the meeting impression View lectures of this symposium